vTv Therapeutics Inc Cash Flow Conversion Efficiency
vTv Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has a cash flow conversion efficiency ratio of -0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($78.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of vTv Therapeutics Inc (2013–2025)
Cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2025. This chart illustrates how vTv Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest vTv Therapeutics Inc stock price today for real-time trading data and today's change.
vTv Therapeutics Inc Cash Flow Conversion Ratio Explained
vTv Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
vTv Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of vTv Therapeutics Inc ranked by their cash flow conversion efficiency. Also see VTVT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
N/A |
|
Inspired Entertainment Inc
NASDAQ:INSE
|
-0.179x |
|
aTyr Pharma, Inc.
NASDAQ:ATYR
|
-0.181x |
|
Thinkific Labs Inc
TO:THNC
|
-0.004x |
|
Guerbet S. A.
PA:GBT
|
0.188x |
|
Chainqui Construction Development Co Ltd
TW:2509
|
-0.053x |
|
Indústrias Romi S.A
SA:ROMI3
|
-0.005x |
|
Fifth District Bancorp, Inc. Common Stock
NASDAQ:FDSB
|
0.007x |
Annual Cash Flow Conversion Efficiency for vTv Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2025. Review free cash flow generation of vTv Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.44 Million | $-25.25 Million | -0.392x | +77.85% |
| 2024-12-31 | $14.30 Million | $-25.31 Million | -1.770x | -272.03% |
| 2023-12-31 | $-18.55 Million | $-19.08 Million | 1.029x | +139.40% |
| 2022-12-31 | $5.84 Million | $-15.25 Million | -2.611x | -105.85% |
| 2021-12-31 | $15.22 Million | $-19.31 Million | -1.268x | +73.27% |
| 2020-12-31 | $3.79 Million | $-18.00 Million | -4.746x | -282.25% |
| 2019-12-31 | $-8.84 Million | $-23.02 Million | 2.604x | +703.31% |
| 2018-12-31 | $-82.85 Million | $-26.86 Million | 0.324x | +9.88% |
| 2017-12-31 | $-151.05 Million | $-44.56 Million | 0.295x | -44.35% |
| 2016-12-31 | $-90.94 Million | $-48.21 Million | 0.530x | +11.87% |
| 2015-12-31 | $-77.97 Million | $-36.95 Million | 0.474x | +667.92% |
| 2014-12-31 | $-498.81 Million | $-30.78 Million | 0.062x | -55.04% |
| 2013-12-31 | $-303.73 Million | $-41.68 Million | 0.137x | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more